Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

(Reuters) -Moderna said on Friday Canada's health regulator has ... including mRESVIA and an experimental COVID-flu ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

which faced market challenges against established Covid-19 vaccine leaders like Pfizer and Moderna. However, Novavax’s ...

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...